These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 8730754)

  • 41. Comparison of the effects of the M1-receptor antagonist telenzepine and the CCK-receptor antagonist loxiglumide on the pancreatic secretory response to intraduodenal tryptophan in dogs.
    Teyssen S; Niebergall-Roth E; Rausch A; Beglinger C; Riepl RL; Chari S; Singer MV
    Pancreas; 1996 Nov; 13(4):407-16. PubMed ID: 8899802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholecystokinin receptor antagonism by peptidergic and non-peptidergic agents in rat pancreas.
    Dembinski A; Jaworek J; Konturek PK; Konturek SJ; Warzecha Z
    J Physiol; 1989 Apr; 411():419-35. PubMed ID: 2614728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
    O'Neill MF; Dourish CT; Iversen SD
    Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
    Nakano S; Tachibana I; Otsuki M
    Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of loxiglumide on pancreatic exocrine secretion stimulated by meal in conscious dogs.
    Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Edano K; Kasai H; Kimura K; Fujii M
    Arzneimittelforschung; 1998 Jan; 48(1):55-7. PubMed ID: 9522033
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of cholecystokinin (CCK)-JMV-180 on the CCK receptors of rabbit pancreatic acini and gallbladder smooth muscle.
    Taniguchi H; Nagasaki M; Tamaki H
    Jpn J Pharmacol; 1995 Mar; 67(3):219-24. PubMed ID: 7543168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.
    D'Amato M; Stamford IF; Bennett A
    Br J Pharmacol; 1991 Feb; 102(2):391-5. PubMed ID: 2015421
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of the specific cholecystokinin-receptor antagonist loxiglumide on bombesin stimulated pancreatic enzyme secretion in man.
    Jebbink MC; Jansen JB; Mooy DM; Rovati LC; Lamers CB
    Regul Pept; 1991 Feb; 32(3):361-8. PubMed ID: 1714084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A cholecystokinin receptor antagonist, loxiglumide, stimulates biliary secretion in conscious rats.
    Watanabe N; Otsuki M
    Eur J Pharmacol; 1994 Nov; 264(3):331-6. PubMed ID: 7698173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PD 135158, a CCKB/gastrin receptor antagonist, stimulates rat pancreatic enzyme secretion as a CCKA receptor agonist.
    Höcker M; Hughes J; Fölsch UR; Schmidt WE
    Eur J Pharmacol; 1993 Sep; 242(1):105-8. PubMed ID: 7901038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Different inhibitory effects of the newly developed CCK receptor antagonists FK480 and KSG-504 on pancreatic exocrine and endocrine secretion in the isolated perfused rat pancreas.
    Kihara Y; Otsuki M
    Pancreas; 1995 Mar; 10(2):109-17. PubMed ID: 7716133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
    Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W
    Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural features of various proglumide-related cholecystokinin receptor antagonists.
    Jensen RT; Zhou ZC; Murphy RB; Jones SW; Setnikar I; Rovati LA; Gardner JD
    Am J Physiol; 1986 Dec; 251(6 Pt 1):G839-46. PubMed ID: 2431626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
    Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M
    Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats.
    Ishizaki K; Kinbara S; Kawamura M; Kimura K; Shiratori K; Takeuchi T
    Pancreas; 2003 Jan; 26(1):87-91. PubMed ID: 12499923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Asperlicin: a unique nonpeptide cholecystokinin antagonist.
    Zucker KA; Adrian TE; Zdon MJ; Ballantyne GH; Modlin IM
    Surgery; 1987 Aug; 102(2):163-70. PubMed ID: 2441481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological characterization of rebamipide: its cholecystokinin CCK1 receptor binding profile and effects on Ca2+ mobilization and amylase release in rat pancreatic acinar cells.
    Moon SJ; An JM; Kim J; Lee SI; Ahn W; Kim KH; Seo JT
    Eur J Pharmacol; 2004 Nov; 505(1-3):61-6. PubMed ID: 15556137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biochemical regulation of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini.
    Pandya PK; Huang SC; Talkad VD; Wank SA; Gardner JD
    Biochim Biophys Acta; 1994 Oct; 1224(1):117-26. PubMed ID: 7948036
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats.
    Imoto I; Yamamoto M; Jia DM; Otsuki M
    Int J Pancreatol; 1997 Dec; 22(3):177-85. PubMed ID: 9444548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis.
    Latorre M; Bartolomé-Nebreda JM; García-López MT; González-Muñiz R; Herranz R; Del Río J; Cenarruzabeitia E
    Pharmacology; 2004 Oct; 72(2):68-76. PubMed ID: 15331911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.